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1. Introduction 
Treatments for HCC are classified into local and systemic therapies. Various local treatment 
modalities, such as resection, local ablation, transcatheter arterial chemoembolization 
(TACE), and liver transplantation, are available at present. The most suitable treatment 
modality for HCC is selected according to the tumor stage, grade of liver dysfunction, and 
performance status of the patient [1,2]. Although the local approaches have been 
demonstrated to yield good outcomes in patients with earlier-stage disease, the usefulness is 
limited to patients with early-stage HCC [3]. TACE is the most widely used for patients with 
HCC who are not suitable candidates for curative surgical resection or local ablation 
therapy, and have preserved liver function (Child-Pugh class A or B). Randomized clinical 
trials (RCTs) and meta-analysis of RCTs on TACE have shown that this treatment modality 
yields a statistically significant improvement of survival in properly selected candidates, 
e.g., patients with multinodular asymptomatic tumors [4,5].  
Despite the local therapies mentioned above yielding successful outcomes at first, the 
patients often develop recurrences or disease progression subsequently. Locoregional 
treatments for intra- and/or extrahepatic tumors in HCC patients with extrahepatic 
metastases may yield some survival benefit; the reported 3- and 5-year survival rates are 
31.0, 9.2 and 4.5%, respectively, in patients administered locoregional treatments [6]. 
However, the survival rate is often dismal in patients with extrahepatic metastases, with the 
median survival time in HCC patients with metastases being 4.6 months. Despite the poor 
survival of patients with major vascular invasion, no effective treatment(s) has been 
established for these patients [3]. Thus, systemic therapy is needed to improve the survival 
of patients with advanced HCC, including those with major vascular invasion and/or 
extrahepatic metastases.  
Chemotherapy is applied for patients with advanced HCC patients who are TACE-
refractory or show major vascular invasion and/or extrahepatic metastases. Various 
studies have investigated the usefulness of combined therapy with anthracycline 
antitumor antibiotic agents, cisplatin and/or fluorouracil, with the reported response 
rates ranging from 14% to 26% and median overall survival (OS) ranging from 8.9 to 
11.6 months [7-9]. However, despite the better response in phase III trials to 
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combination chemotherapy as compared to doxorubicin monotherapy, no standard 
chemotherapy was identified that could clearly prolong the survival [10]. On the other 
hand, in Japan, various hepatic arterial infusion chemotherapy regimens have been 
applied for patients with very advanced HCCs, such as those with extensive portal vein 
tumor thrombosis, and for some of these regimens, responses rates of more than 40% 
have been reported [11,12]. However, so far, no standard regimen has been identified 
based on large prospective clinical trials that can clearly prolong the survival in patients 
with advanced HCC. 
Some growth factors and various signal transduction pathways have been identified in 
HCCs, and various targeted agents have been investigated for the treatment of patients with 
HCC. These therapies may target not only tumor cell proliferation, but also angiogenesis. 
Sorafenib is a small-molecule multikinase inhibitor that inhibits kinases such as Raf kinase, 
vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor 
receptor (PDGFR)-┚ tyrosine kinases. It is the first agent that was demonstrated to yield 
survival benefit in patients with unresectable advanced HCC [13,14]. Subsequently, various 
targeted agents have been investigated for the treatment of HCC in various stages of 
progression. On the other hand, various characteristic toxicities of molecular targeted 
agents, such as hand-foot syndrome or hypertension, have been reported [13,14,15]. It is 
important to understand the efficacy and safety of molecular targeted therapy to gauge their 
true benefit.  
2. Systemic therapy using targeted agents for advanced HCC 
2.1 Summary of pivotal trilas of sorafenib 
Sorafenib is a small-molecule multikinase inhibitor that inhibits kinases such as Raf 
kinase, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth 
factor receptor (PDGFR)-┚ tyrosine kinases [16]. In a phase I study of sorafenib conducted 
in 69 patients with solid malignant tumors, diarrhea was the most commonly encountered 
treatment-related adverse event, and the dose-limiting toxicities were diarrhea, fatigue, 
and skin toxicities, namely, hand-foot syndrome and rash [17]. The maximum tolerated 
dose was found to be 400 mg bid continuous and the recommended dose of sorafenib for 
future studies was also 400 mg bid as a continuous dosing schedule. In regard to the 
efficacy, even a partial response (PR) was observed in only one of the 45 patients treated 
continuously with sorafenib at doses of > 100 mg bid, who was a patient of HCC treated 
with the drug at 400 mg bid. In this phase I study, six HCC patients were assessable for 
efficacy, of which one showed PR, 4 showed stable disease (SD), and one showed 
progressive disease (PD). Based on these preclinical results and the results of the phase I 
study of sorafenib, a phase II study was performed in 137 patients with advanced HCC 
[18]. Although the response rate was low (2.2%), the time-to progression (TTP) and overall 
survival (OS) were more promising (Table 1).  
Based on these results, a large randomized controlled trial (RCT) of sorafenib versus placebo 
(the SHARP trial) was conducted in patients with advanced HCC and good liver function 
(Child-Pugh A)[13]. Six hundred two patients were randomized into two arms, namely, the 
sorafenib arm and the placebo arm (Table 1). The TTP was 5.5 months for sorafenib and 2.8 
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months for placebo, and the hazard ratio in the sorafenib arm was 0.58 (95% CI: 0.45-0.74; 
p<0.001). The median OS was 10.7 months in the sorafenib arm and 7.9 months in the 
placebo arm, and the hazard ratio for OS in the sorafenib arm was 0.69 (95% CI: 0.55-0.87; 
p<0.001). Thus, sorafenib was the first systemic chemotherapeutic agent demonstrated to 
prolong survival in patients with advanced HCC. 
Agent 
Study 
setting 
n 
Response 
rate 
Median 
TTP 
Median 
OS 
p-value 
(HR, 95%CI)
Author 
(year) 
Sorafenib Phase II 137 2% 4.2 mo 9.2 mo - 
Abou-Alfa  
(2006) [18] 
Sorafenib Phase I 27 4% 4.9 mo 15.6 mo - 
Furuse     
(2008) [19] 
Sorafenib 
Phase III
299 2.3% 5.5 mo 10.7 mo P < 0.001 
(0.69, 0.55-
0.87) 
Llovet      
(2008) [13] 
Placebo 303 0.7% 2.8 mo 7.9 mo 
Sorafenib 
Phase III
150 3.3% 2.8 mo 6.5 mob P = 0.0155 
(0.67, 0.49-
0.93) 
Cheng     
(2009) [14] 
Placebo 76 1.3% 1.4 mo 4.2 mo 
TTP, time-to progression; OS, overall survival; HR, hazard ratio; CI, confidence interval 
Table 1. Clinical trials of sorafenib for hepatocellular carcinoma. 
In the SHARP trial, approximately 90% of the patients enrolled were from Europe or 
Australia. The differences in the efficacy and safety was a concern in relation to the 
application of sorafenib as a global standard therapeutic agent for advanced HCC, as the 
etiology and treatment strategies for HCC vary among regions in the world. Therefore, to 
confirm the efficacy and safety of the drug in Asian populations, a RCT of sorafenib was 
conducted in the Asia-Pacific region (the Asia-Pacific trial)[14]. The dosing schedule of 
sorafenib was the same as that used in the SHARP trial, namely, continuous administration 
of 400 mg bid, and the patients were randomized 2:1 to sorafenib or placebo. The median 
OS, which was the primary endpoint, was 6.5 months for sorafenib and 4.2 months for 
placebo, and the hazard ratio for OS in the sorafenib arm was 0.67 (95% CI: 0.49-0.93; 
p=0.0155) [14]. 
Despite the equivalent hazard ratio for OS and TTP in the two RCTs, the median OS and 
TTP were very poor in the Asia-Pacific trial as compared with that in the SHARP trial. This 
was considered to be attributable to the differences in the patient characteristics, such as the 
poorer performance status (69% of ECOG PS) and more advanced stage of the cancer in the 
latter trial (96% with BCLC stage C, 52% with lung metastases).  
Since patients enrolled in the SHARP trial and Asia-Pacific trial were limited to those with 
good liver function (Child-Pugh A), the usefulness of sorafenib needed to be examined in 
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patients with Child-Pugh class B, or moderate liver dysfunction. In a phase II study of 
sorafenib, 38 out of the 137 patients enrolled were classified into Child-Pugh class B [18]. 
This study revealed some variability in the AUC and Cmax values, which were slightly 
greater in the Child-Pugh class B patients than in the Child-Pugh class A patients, 
however, the differences were not significant [18]. In Japan, a phase I study of sorafenib 
was conducted to investigate the pharmacokinetics, safety and efficacy of the drug in 
Japanese patients with advanced HCC; the study included an equal number of Child-
Pugh class A and B patients [19]. In regard to the differences in the pharmacokinetics 
between the Child-Pugh class A and B patients, although both the area under the 
concentration-time curve for 0-12 h and the maximal concentration in the steady state 
were slightly lower in the Child-Pugh class B patients than in the Child-Pugh class A 
patients, there were no major differences in the incidence or grade of drug-related adverse 
events between the Child-Pugh class A and B groups; however, hypertension, hand-foot 
skin reactions, and rash were reported more frequently in the Child-Pugh class B group 
[18]. Especially, grade 3-4 adverse events of elevated bilirubin, ascites, and 
encephalopathy occurred at a greater frequency in Child-Pugh class B patients than in the 
Child-Pugh class A patients [20]. Thus, the efficacy or safety of sorafenib in HCC patients 
categorized as Child-Pugh class B are not clear yet. 
The most commonly reported toxicities of sorafenib are transient elevation of lipase and/or 
amylase, rash/desquamation, hand-foot skin reaction, diarrhea, anorexia, weight loss, 
alopecia, and voice changes. The reported drug-related adverse events of grade 3 or greater 
severity are diarrhea, hand-foot skin reaction, hypertension and rash. 
2.2 Indications of sorafenib in the treatment of HCC 
The Barcelona Clinic Liver Cancer (BCLC) staging classification has been employed as a 
guide for treatment selection in HCC patients [21]. Based on the results of RCTs of sorafenib, 
BCLS Stage C (advanced stage), which includes portal invasion, lymph node metastasis, 
and/or distant metastasis, has been reported as a suitable criterion for the selection of 
sorafenib. The Japanese consensus-based treatment algorithm also recommends treatment 
for HCC according to the tumor stage and degree of impairment of liver function [2]. In this 
algorithm, sorafenib is recommended as the first-line therapy for advanced HCC patients 
classified as Child-Pugh class A, who show extrahepatic spread or major vascular invasion 
and/or are TACE-refractory.  
2.3 Recent trials using new targeted agents 
Phase I, phase II studies have been conducted to investigate the usefulness of various 
new targeted agents for the treatment of advanced HCC (Table 2). Some large phase III 
studies of new targeted agents alone or such agents in combination with sorafenib vs. 
sorafenib alone have also been conducted. Some multikinase inhibitors, such as 
sunitinib, brivanib and linifanib, that have shown promising antitumor activity against 
HCC in phase II studies [22-25] have been investigated in head-to-head study 
comparisons with sorafenib (Table 3). Some phase III studies comparing sorafenib in 
combination with another molecular targeted agent or cytotoxic agent vs. sorafenib alone 
are also under way. 
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Agent 
Study 
setting 
n 
Response 
rate 
Median 
TTP/PFS 
Median  
OS 
Author (Year) 
Sunitinib 
Phase II 37 2.7% 5.3 mo 8.0 mo Faivre (2009) [22] 
Phase II 45 2.9% 3.9 mo 9.3 mo Zhu (2009) [23] 
Brivanib Phase II 55 7.3% 2.7 mo 10.0 mo Park (2011) [24] 
Linifanib Phase II 44 6.8% 3.7 mo 9.3 mo Toh (2009) [25] 
Everolimus Phase I/II 28 4% 3.8 mo 8.4 mo Zhu (2010) [26] 
TSU-68 Phase I/II 35 2.9% 2.1 mo 13.1 mo Kanai (2010) [27] 
Sunitinib 
Phase III 
529 6% 4.1 mo 8.1 mo* 
Cheng (2011) [28] 
Sorafenib 554 6% 4.0 mo 10.0 mo 
TTP, time-to progression; PFS, progression-free survival; OS, overall survival 
*hazard ratio 1.31 (95% confidence interval: 1.13-1.52), P = 0.0019 
Table 2. Clinical trials of new molecular targeted agents for hepatocellular carcinoma. 
 
Study setting Agent 
1. First-line chemotherapy sunitinib, brivanib, linifanib 
2. Second-line chemotherapy brivanib, everolimus, ramcirumab, axitinib* 
3. Combination with TACE sorafenib, brivanib, TSU-68  
4. Adjuvant therapy after resection or ablation sorafenib  
TACE, transarterial chemoembolization 
* randomized phase II study 
Table 3. Molecular targeted agents developing in randomized clinical trials  
The estimated time-to progression in patinets treated with sorafenib ranges from 2.8 to 5.5 
months and some patients may accrue benefits of second-line chemotherapy after being 
labeled as sorafenib-refractory. Some large phase III studies of new targeted agents, such as 
brivanib, everolimus and ramcirumab, as second-line treatment have also been conducted 
(Table 3). 
Among these phase III studies, the results of a phase III study comparing sunitinib with 
sorafenib was reported in 2011. The trial did not show any survival advantage of sunitinib 
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in pateints with advanced HCC; in fact, the survival in the sunitinib group was inferior to 
that in the sorafenib group (Table 3) [28]. 
3. Combined molecular targeted therapy with local therapy 
3.1 Combination with TACE 
Transcatheter arterial chemoembolization is widely applied for the treatment of HCC as one 
of the standard treatments along with resection and local ablation. One-third of all patients 
with primary HCC are treated by TAE/TACE as the first-line treatment [2]. However, the 
Nationwide Follow-up Survey by the Liver Cancer Study Group of Japan (LCSGJ) revealed 
that the 5-year survival rates for resection, ablation and TACE were 59.2%, 48.4% and 29.7%, 
respectively, for single tumors, and 46.4%, 37.3% and 23.0%, respectively, for two tumors; 
thus, the efficacy in terms of survival prolongation of TACE was limited as compared with 
that of resection and ablation [2]. It is difficult to obtain complete necrosis of tumors by 
TACE, and the reported objective response rate to TACE ranges from 15%-55% [29]. Thus, to 
improve the efficacy of TACE, combined use of TACE with molecular targeted therapy has 
been investigated.  
Regarding the increment of the serum VEGF level associated with TACE, it was reported 
that the serum VEGF increased within 1 to 2 days after TACE and recovered by one month 
later; also, an association between the serum VEGF level and the prognosis after TACE in 
HCC patients has been reported. Therefore, it may be reasonable to suppress the effects of 
VEGF by VEGFR inhibitors to improve the survival benefit yielded by TACE in patients 
with HCC [30]. 
The first trial of combined TACE with molecular targeted agents was a placebo-controlled 
phase III study of sorafenib (post TACE study) conducted in Japan and Korea [31]. The 
primary endpoint was the TTP, and to prove the assumption that the median TTP would be 
50% higher in the sorafenib than in the placebo group. The median TTP in the sorafenib and 
placebo groups was 5.4 and 3.7 months, respectively (hazard ratio (HR), 0.87; 95% 
confidence interval, 0.70-1.09; P = 0.252). Although the TTP in the sorafenib group was 
better than that in the placebo group, the drug yielded no statistically significant 
prolongation of the TTP after TACE. This study was designed before the results of the 
SHARP and Asia-Pacific trials of sorafenib were reported, and only patients who responded 
to TACE were included as the subjects of this study. As a result, it took a median of 9.3 
weeks from TACE to randomization, because the efficacy of TACE could only be evaluated 
by CT one month after the procedure, and a central review of CT findings was required. 
Currently, many comparative studies between TACE plus a targeted agent and TACE alone 
are under way (Table 3). In these studies, administration of targeted agents is initiated 
before TACE or as soon as possible after TACE.  
3.2 Adjuvant therapy with targeted agents after curative treatments 
One of characteristics of HCC is the very high recurrence rate after regional therapies. Even 
for early-stage HCCs (smaller than 3 cm and 3 or less in number), the reported cumulative 1- 
and 5-year recurrence rates after resection are 24.5% and 74.3%, respectively [32]. There are 
two mechanisms of recurrence after curative treatments, that is, metastasis from the primary 
www.intechopen.com
 
Molecular Targeted Therapy for Growth Factors in Hepatocellular Carcinoma 
 
327 
HCC lesion and new multicentric development. Patients with HCC have microscopic 
lesions, and intrahepatic metastases often develop rather early after curative treatments. On 
the other hand, patients with HCC are also at a greater risk of multicentric 
hepatocarcinogenesis and de novo development of HCC tumors [33].  
Thus, various adjuvant therapies have been investigated to suppress the risk of recurrence 
after curative treatments, including resection and ablation therapy. An acyclic retinoid, 
polyprenoic acid, was reported to prevent the development of second primary hepatomas 
after surgical resection or percutaneous injection of ethanol in a small randomized 
comparison trial [34]. Peretinoin, an acyclic retinoid, administered at the dose of 600 mg 
statistically significantly decreased the 2-year recurrence rate as compared with placebo in a 
large RCT, however, no improvement of the primary endpoint, that is, of the recurrence-free 
survival, was observed, therefore, the efficacy is still unclear [35]. It was reported that 
adoptive immunotherapy may also improve the recurrence-free outcomes after surgery for 
HCC [36], but it has not yet been applied for adjuvant therapy in the clinical setting because 
of the complicated method of its use. While interferon or vitamin K have been suggested as 
having potential activity for suppressing recurrence, so far, no standard adjuvant therapy 
regimen including these agents has been established [37-39].  
In a prospective study consisting 57 patients with HCC who underwent resection, high 
expression levels of PDGFR-┙ and PDGFR-┚ were independently associated with decreased 
survival [40]. Molecular targeted agents are expected to suppress the recurrence rate of HCC 
after curative treatments. Sorafenib is also currently under investigation as an adjuvant 
therapy after curative treatment(s). 
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surgeons, interventional and diagnostic radiologists, pathologists and epidemiologists. General surgeons,
general physicians, trainees, hospital administrators, and instruments and drug manufacturers will also find
this book useful as a reference.
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